This high dose nusinersen regimen for spinal muscular atrophy includes 50mg loading doses and 28mg maintenance doses.
Zacks Investment Research on MSN
Biogen secures FDA nod for higher dose of SMA drug Spinraza
Shares of Biogen BIIB rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster ...
Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain autoimmune conditions. Ultomiris is given as an intravenous (IV) infusion by a healthcare professional. The drug’s dosing ...
The FDA has approved a higher-dose regimen of Spinraza for spinal muscular atrophy, providing a new treatment option for patients. The regimen includes 50 milligram per 5 milliliter and 28 milligram ...
The FDA approved a high-dose nusinersen regimen for spinal muscular atrophy, offering pharma teams key insights into dose ...
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in ...
After a surprise rejection in September last year, the FDA has signed off on a high-dose formulation of Biogen’s spinal muscular atrophy drug Spinraza. The approval, announced Monday, will allow a ...
Please provide your email address to receive an email when new articles are posted on . Topline data from an ongoing clinical trial of a higher dose regimen of Spinraza in treatment-naive, symptomatic ...
Ultomiris is administered intravenously by a healthcare professional, with infusion times varying from 24 to 90 minutes or more depending on the dose. The dosage of Ultomiris is determined by body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results